AS Latvijas Juras medicinas centrs

As of December 31, 2025, AS Latvijas Juras medicinas centrs has 800,000.00 shares outstanding.

As of December 31, 2025, AS Latvijas Juras medicinas centrs trades at a trailing price-to-earnings ratio of 29.54. The price-to-sales ratio is 0.69, and the price-to-book ratio stands at 1.93.

As of December 31, 2025, AS Latvijas Juras medicinas centrs maintains a current ratio of 0.86, meaning it holds 0.9x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended December 31, 2025, AS Latvijas Juras medicinas centrs posted a return on equity (ROE) of 6.68, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 2.71, measuring how efficiently the asset base is converted into earnings. Return on capital employed (ROCE) is 6.68, useful for judging operating efficiency across full business cycles. Inventory turnover of 72.60 indicates how many times AS Latvijas Juras medicinas centrs sells and replaces its inventory over a year, a key working capital efficiency ratio.

These figures cover the twelve months ended December 31, 2025. That works out to an effective tax rate of 6.69, which can sit above or below the statutory corporate tax rate depending on foreign earnings mix, tax credits, and one-off items.

Over the twelve months ended December 31, 2025, AS Latvijas Juras medicinas centrs posted a gross margin of 7.13, reflecting its pricing power and cost economics. The operating margin of 1.10 and net profit margin of 2.34 provide insight into operational efficiency.

These figures cover the twelve months ended December 31, 2025. Free cash flow yield stands at 2.44, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 1.12, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to AS Latvijas Juras medicinas centrs shareholders.

As of December 31, 2025, AS Latvijas Juras medicinas centrs has an Altman Z-Score of 3.38, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.